Clinical Trial

Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a prospective, phase II clinical trial with the primary objective of assessing the effectiveness of demethylating agents combined with venetoclax in the prevention of recurrence after allogeneic hematopoietic stem cell transplantation (allo-HSCT) of high risk T-lymphoblastic lymphoma/leukemia (T-LBL/ALL) patients.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-11-11; most recent amendment 2025-05-04.
Trial Details
NCT Number NCT06686108
Lead Sponsor Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Conditions T-cell Acute Lymphoblastic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Relapse
Enrollment 59 participants
Start Date 2024-10-30
Primary Completion 2027-10-30 (estimated)
Study Completion 2028-10-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-07